Gossamer Bio (GOSS) Competitors $1.30 +0.05 (+3.60%) As of 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock GOSS vs. CALT, GPCR, AUPH, WVE, NAGE, MLYS, RCUS, SYRE, AKBA, and CVACShould you be buying Gossamer Bio stock or one of its competitors? The main competitors of Gossamer Bio include Calliditas Therapeutics AB (publ) (CALT), Structure Therapeutics (GPCR), Aurinia Pharmaceuticals (AUPH), Wave Life Sciences (WVE), Niagen Bioscience (NAGE), Mineralys Therapeutics (MLYS), Arcus Biosciences (RCUS), Spyre Therapeutics (SYRE), Akebia Therapeutics (AKBA), and CureVac (CVAC). These companies are all part of the "pharmaceutical products" industry. Gossamer Bio vs. Calliditas Therapeutics AB (publ) Structure Therapeutics Aurinia Pharmaceuticals Wave Life Sciences Niagen Bioscience Mineralys Therapeutics Arcus Biosciences Spyre Therapeutics Akebia Therapeutics CureVac Gossamer Bio (NASDAQ:GOSS) and Calliditas Therapeutics AB (publ) (NASDAQ:CALT) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, media sentiment, dividends, institutional ownership, community ranking and earnings. Which has more risk and volatility, GOSS or CALT? Gossamer Bio has a beta of 1.85, indicating that its share price is 85% more volatile than the S&P 500. Comparatively, Calliditas Therapeutics AB (publ) has a beta of 1.77, indicating that its share price is 77% more volatile than the S&P 500. Do institutionals & insiders have more ownership in GOSS or CALT? 81.2% of Gossamer Bio shares are owned by institutional investors. Comparatively, 2.8% of Calliditas Therapeutics AB (publ) shares are owned by institutional investors. 6.7% of Gossamer Bio shares are owned by company insiders. Comparatively, 2.2% of Calliditas Therapeutics AB (publ) shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Do analysts recommend GOSS or CALT? Gossamer Bio currently has a consensus target price of $7.75, suggesting a potential upside of 498.46%. Given Gossamer Bio's stronger consensus rating and higher possible upside, research analysts plainly believe Gossamer Bio is more favorable than Calliditas Therapeutics AB (publ).Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Gossamer Bio 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00Calliditas Therapeutics AB (publ) 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is GOSS or CALT more profitable? Gossamer Bio has a net margin of 0.00% compared to Calliditas Therapeutics AB (publ)'s net margin of -30.18%. Gossamer Bio's return on equity of -127.28% beat Calliditas Therapeutics AB (publ)'s return on equity.Company Net Margins Return on Equity Return on Assets Gossamer BioN/A -127.28% -22.12% Calliditas Therapeutics AB (publ) -30.18%-212.04%-27.96% Does the MarketBeat Community prefer GOSS or CALT? Gossamer Bio received 130 more outperform votes than Calliditas Therapeutics AB (publ) when rated by MarketBeat users. Likewise, 67.09% of users gave Gossamer Bio an outperform vote while only 55.10% of users gave Calliditas Therapeutics AB (publ) an outperform vote. CompanyUnderperformOutperformGossamer BioOutperform Votes15767.09% Underperform Votes7732.91% Calliditas Therapeutics AB (publ)Outperform Votes2755.10% Underperform Votes2244.90% Which has stronger valuation & earnings, GOSS or CALT? Calliditas Therapeutics AB (publ) has higher revenue and earnings than Gossamer Bio. Calliditas Therapeutics AB (publ) is trading at a lower price-to-earnings ratio than Gossamer Bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGossamer Bio$124.59M2.36-$179.82M-$0.23-5.63Calliditas Therapeutics AB (publ)$1.60B0.74-$43.96M-$1.85-21.62 Does the media favor GOSS or CALT? In the previous week, Gossamer Bio had 8 more articles in the media than Calliditas Therapeutics AB (publ). MarketBeat recorded 8 mentions for Gossamer Bio and 0 mentions for Calliditas Therapeutics AB (publ). Gossamer Bio's average media sentiment score of 1.35 beat Calliditas Therapeutics AB (publ)'s score of 0.00 indicating that Gossamer Bio is being referred to more favorably in the media. Company Overall Sentiment Gossamer Bio Positive Calliditas Therapeutics AB (publ) Neutral SummaryGossamer Bio beats Calliditas Therapeutics AB (publ) on 16 of the 18 factors compared between the two stocks. Get Gossamer Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for GOSS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GOSS vs. The Competition Export to ExcelMetricGossamer BioPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$284.13M$6.82B$5.57B$8.67BDividend YieldN/A2.49%5.27%4.19%P/E Ratio-3.918.7927.2620.17Price / Sales2.28263.83424.24161.98Price / CashN/A65.8538.2534.64Price / Book4.466.677.124.72Net Income-$179.82M$143.49M$3.23B$247.80M7 Day Performance-0.79%5.15%3.79%2.75%1 Month Performance12.61%15.42%13.37%9.70%1 Year Performance144.91%6.02%32.03%14.51% Gossamer Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GOSSGossamer Bio4.0181 of 5 stars$1.30+3.6%$7.75+498.5%+142.7%$294.36M$124.59M-4.05180Positive NewsAnalyst RevisionCALTCalliditas Therapeutics AB (publ)N/A$40.00flatN/AN/A$1.19B$1.60B-21.62180GPCRStructure Therapeutics1.9401 of 5 stars$20.51-2.9%$76.50+273.0%-58.7%$1.18BN/A-27.72136News CoveragePositive NewsAnalyst RevisionAUPHAurinia Pharmaceuticals3.2916 of 5 stars$8.14-0.6%$11.50+41.3%+50.9%$1.10B$247.30M-54.26300Positive NewsAnalyst RevisionWVEWave Life Sciences4.3506 of 5 stars$7.05-2.4%$21.17+200.2%+22.5%$1.09B$104.94M-6.35240Positive NewsAnalyst ForecastAnalyst RevisionNAGENiagen Bioscience1.3961 of 5 stars$13.43+3.7%$18.00+34.0%N/A$1.06B$107.93M79.00120News CoverageAnalyst ForecastMLYSMineralys Therapeutics2.7194 of 5 stars$16.19+0.4%$38.00+134.7%+18.7%$1.06BN/A-4.4528Positive NewsAnalyst ForecastRCUSArcus Biosciences2.752 of 5 stars$9.86-1.1%$24.13+144.7%-37.7%$1.04B$141M-3.13500News CoverageOptions VolumeAnalyst RevisionGap UpSYRESpyre Therapeutics2.2677 of 5 stars$17.16+1.1%$53.40+211.2%-49.1%$1.03B$890,000.00-2.3073AKBAAkebia Therapeutics4.3528 of 5 stars$3.83-3.5%$6.75+76.2%+259.6%$1.01B$184.91M-16.65430High Trading VolumeCVACCureVac4.0923 of 5 stars$4.48+1.6%$11.00+145.5%-7.0%$1.01B$523.70M8.15880 Related Companies and Tools Related Companies CALT Competitors GPCR Competitors AUPH Competitors WVE Competitors NAGE Competitors MLYS Competitors RCUS Competitors SYRE Competitors AKBA Competitors CVAC Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GOSS) was last updated on 6/11/2025 by MarketBeat.com Staff From Our PartnersYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredWhy July 22nd Could Mean Big Changes for Social SecurityIn a stunning move, President Trump has authorized an AI-led transformation of federal agencies, including Soc...Altimetry | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Gossamer Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Gossamer Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy GOSS Stock Free GOSS Stock Alerts